– Wednesday’s vote came just two days after FDA staff reviewers recommended against accelerated approval for the candidate, citing concerns with the trial method and outcomes, specifically the possibility for investigator bias. – The former jab failed to reach endpoints for non-small cell lung cancer and previously failed to outperform placebo in a melanoma trial April 29, 2015 | By Eric …